What is DEXLEVO?
Founded in 2012 and headquartered in Seoul, South Korea, DEXLEVO is a key player in the aesthetic medical products sector. The company leverages advanced biopolymer technology specifically targeted at skin care solutions. Its specialization in this niche positions it within a growing global market for advanced dermatological and cosmetic treatments.
How much funding has DEXLEVO raised?
DEXLEVO has raised a total of $22M across 1 funding round:
Other Financing Round
$22M
Other Financing Round (2021): $22M with participation from Magna Investment, Smilegate Investment, HYUNDAI VENTURE INVESTMENT, and Shinhan Financial Group
Key Investors in DEXLEVO
Magna Investment
Magna Investment is a private investment firm focused on building sustainable growth and creating lasting impact through strategic investments across various asset classes. They aim to contribute to economic advancement while adhering to Sharia principles.
Smilegate Investment
Smilegate Investment is an entity involved in the investment sector. Further details regarding their specific investment focus or operational scope were not provided in the available data.
HYUNDAI VENTURE INVESTMENT
Hyundai Venture Investment Corp operates within the Venture Capital & Private Equity industry, headquartered in Seoul, South Korea. They are known for investing in various technology and growth-stage companies.
What's next for DEXLEVO?
The substantial enterprise-level funding, including the major strategic investment in December 2021, indicates DEXLEVO is poised for significant scaling and market expansion. This capital infusion will likely fuel further research and development in biopolymer technology, enhance manufacturing capabilities, and broaden its distribution network for aesthetic medical products. The company's focus on skin care solutions suggests a strategic move to capitalize on increasing consumer demand for non-invasive and technologically advanced treatments.
See full DEXLEVO company page
